Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27101955 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL6539320 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL604896 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL16486263 | 0.79 | ACHE (0.44) | ALDH1A1ACHE | |
| SCHEMBL604897 | 0.79 | CHRNB2 (0.54) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL8381807 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL10120804 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL15148136 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL6538861 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL21400836 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-0837870-A1 | SYNTHETIC MODIFICATION TO SPINOSYN COMPOUNDS | DOWELANCO (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997000265-A1 | SYNTHETIC MODIFICATION TO SPINOSYN COMPOUNDS | DOWELANCO (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | SMN1; SMN2 2439/4885ALDH1A1 578/4885LMNA 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.